The inhibitory role of miR‑485‑5p in colorectal cancer proliferation and invasion via targeting of CD147

Pan,Yuqin; Sun,Huiling; Hu,Xiuxiu; He,Bangshun; Liu,Xiangxiang; Xu,Tao; Chen,Xiaoxiang; Zeng,Kaixuan; Wang,Shukui

doi:10.3892/or.2018.6309

The inhibitory role of miR‑485‑5p in colorectal cancer proliferation and invasion via targeting of CD147

Authors:
- Yuqin Pan
- Huiling Sun
- Xiuxiu Hu
- Bangshun He
- Xiangxiang Liu
- Tao Xu
- Xiaoxiang Chen
- Kaixuan Zeng
- Shukui Wang
View Affiliations

Affiliations: Central Laboratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: March 12, 2018 https://doi.org/10.3892/or.2018.6309
Pages: 2201-2208

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recently, miR‑485‑5p was identified as a tumor‑suppressing microRNA in some human cancers. However, the expression and biological role of miR‑485‑5p in colorectal cancer (CRC) remain unclear. Herein, we found that the expression of miR‑485‑5p in CRC tissues and cell lines was much lower than that in the control, respectively. Moreover, the overexpression of miR‑485‑5p could inhibit the proliferation and invasion of CRC cell lines in vitro and in vivo. Furthermore, we determined that miR‑485‑5p could decrease the expression of CD147 by directly targeting CD147 3'UTR. In addition, the expression of CD147 was inversely correlated with the expression of miR‑485‑5p in CRC tissues. Collectively, our results revealed that miR‑485‑5p played a pivotal tumor‑suppressing role in CRC through downregulation of cancer‑associated gene CD147, and may provide a better understanding of the pathogenesis in CRC and a new bio‑target for CRC therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Ciombor KK, Wu C and Goldberg RM: Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 66:83–95. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ren A, Dong Y, Tsoi H and Yu J: Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci. 16:2810–2823. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zeng CY, Zhan YS, Huang J and Chen YX: MicroRNA-7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase. Mol Med Rep. 13:1297–1303. 2016. View Article : Google Scholar : PubMed/NCBI
5	Slaby O: Non-coding RNAs as biomarkers for colorectal cancer screening and early detection. Adv Exp Med Biol. 937:153–170. 2016. View Article : Google Scholar : PubMed/NCBI
6	Jiang L, Cheng Q, Zhang BH and Zhang MZ: Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: A validation set from China. Medicine (Baltimore). 94:e6032015. View Article : Google Scholar : PubMed/NCBI
7	Khoury S and Tran N: Circulating microRNAs: Potential biomarkers for common malignancies. Biomark Med. 9:131–151. 2015. View Article : Google Scholar : PubMed/NCBI
8	He N, Zheng H, Li P, Zhao Y, Zhang W, Song F and Chen K: miR-485-5p binding site SNP rs8752 in HPGD gene is associated with breast cancer risk. PLoS One. 9:e1020932014. View Article : Google Scholar : PubMed/NCBI
9	Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G and An HJ: Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology. 57:734–743. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kang M, Ren MP, Zhao L, Li CP and Deng MM: miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 7:2212–2222. 2015.PubMed/NCBI
11	Chen Z, Li Q, Wang S and Zhang J: miR-485-5p inhibits bladder cancer metastasis by targeting HMGA2. Int J Mol Med. 36:1136–1142. 2015. View Article : Google Scholar : PubMed/NCBI
12	Rosenthal EL, Shreenivas S, Peters GE, Grizzle WE, Desmond R and Gladson CL: Expression of extracellular matrix metalloprotease inducer in laryngeal squamous cell carcinoma. Laryngoscope. 113:1406–1410. 2003. View Article : Google Scholar : PubMed/NCBI
13	Gallagher SM, Castorino JJ, Wang D and Philp NJ: Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res. 67:4182–4189. 2007. View Article : Google Scholar : PubMed/NCBI
14	Sato M, Nakai Y, Nakata W, Yoshida T, Hatano K, Kawashima A, Fujita K, Uemura M, Takayama H and Nonomura N: EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. PLoS One. 8:e743132013. View Article : Google Scholar : PubMed/NCBI
15	Omi Y, Shibata N, Okamoto T, Obara T and Kobayashi M: The role of CD147 in the invasiveness of follicular thyroid carcinoma cells. Thyroid. 22:383–394. 2012. View Article : Google Scholar : PubMed/NCBI
16	Stenzinger A, Wittschieber D, von Winterfeld M, Goeppert B, Kamphues C, Weichert W, Dietel M, Rabien A and Klauschen F: High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Hum Pathol. 43:1471–1481. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhu S, Chu D, Zhang Y, Wang X, Gong L, Han X, Yao L, Lan M, Li Y and Zhang W: EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol. 30:3692013. View Article : Google Scholar : PubMed/NCBI
18	Zheng HC, Wang W, Xu XY, Xia P, Yu M, Sugiyama T and Takano Y: Up-regulated EMMPRIN/CD147 protein expression might play a role in colorectal carcinogenesis and its subsequent progression without an alteration of its glycosylation and mRNA level. J Cancer Res Clin Oncol. 137:585–596. 2011. View Article : Google Scholar : PubMed/NCBI
19	Pan Y, He B, Song G, Bao Q, Tang Z, Tian F and Wang S: CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells. Oncol Rep. 27:2003–2009. 2012.PubMed/NCBI
20	Pan Y, He B, Chen J, Sun H, Deng Q, Wang F, Ying H, Liu X, Lin K, Peng H, et al: Gene therapy for colorectal cancer by adenovirus-mediated siRNA targeting CD147 based on loss of the IGF2 imprinting system. Int J Oncol. 47:1881–1889. 2015. View Article : Google Scholar : PubMed/NCBI
21	Gray RT, Coleman HG, Hughes C, Murray LJ and Cardwell CR: Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiol. 45:71–81. 2016. View Article : Google Scholar : PubMed/NCBI
22	Lou C, Xiao M, Cheng S, Lu X, Jia S, Ren Y and Li Z: miR-485-3p and miR-485-5p suppress breast cancer cell metastasis by inhibiting PGC-1α expression. Cell Death Dis. 7:e21592016. View Article : Google Scholar : PubMed/NCBI
23	Guo GX, Li QY, Ma WL, Shi ZH and Ren XQ: MicroRNA-485-5p suppresses cell proliferation and invasion in hepatocellular carcinoma by targeting stanniocalcin 2. Int J Clin Exp Pathol. 8:12292–12299. 2015.PubMed/NCBI
24	Li R, Pan Y, He B, Xu Y, Gao T, Song G, Sun H, Deng Q and Wang S: Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo. Int J Oncol. 43:1885–1894. 2013. View Article : Google Scholar : PubMed/NCBI